Prana Bio Ltd Ads S1 (PRAN) 4.92 $PRAN
Prana Alzheimer's disease data features at world leading conference
BusinessWire - Wed Jul 27, 11:22AM CDT
Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana's lead candidate for Huntington and Alzheimer's diseases, at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada on July 26, 2016.
PRAN: 4.92 (-0.34)
Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnology, and Sucampo Pharma
PR Newswire - Fri Jul 24, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ: PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free research report on Synergy Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SYGP On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SGYP: 4.76 (+0.03), OREX: 3.92 (-0.01), SCMP: 11.10 (+0.14), TEVA: 50.90 (+0.51), PRAN: 4.92 (-0.34)
Progressive Supranuclear Palsy Pipeline Review, H1 2015 - 6 Companies & 10 Drug Profiles
M2 - Thu Jun 25, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3grv7/progressive) has announced the addition of the "Progressive Supranuclear Palsy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlzProtect SAS - Bristol-Myers Squibb Company - Prana Biotechnology Limited - ProteoTech, Inc. - Sellas Inc. - TauRx Therapeutics Ltd. Drug Profiles - AZP-2006 - BMS-986168 - DC-TAB - DP-C016 - PBT-434 - PTI-51CH3 - PTI-51CH3 Backup - TPI-287 - TRx-0237 - zolpidem tartrate For more information visit http://www.researchandmarkets.com/research/d3...rogressive
BMY: 56.76 (-0.63), PRAN: 4.92 (-0.34)
Stock to Watch: Prana Biotechnology Up 7.4% (PRAN)
Comtex SmarTrend(R) - Mon Jun 01, 10:19AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 7.4% to $1.47 on 1.3x average daily volume. Prana Biotechnology has traded 1.0 million shares thus far today, vs. average volume of 789,000 shares per day. The stock has outperformed the Dow (7.4% to the Dow's 0.2%) and outperformed the S&P 500 (7.4% to the S&P's 0.1%) during today's trading.
PRAN: 4.92 (-0.34)
European Commission Approves PBT2 Orphan Designation for Huntington's Disease
BusinessWire - Mon Jun 01, 8:00AM CDT
Prana Biotechnology Limited (ASX BT/NASDAQ RAN) has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington's disease.
PRAN: 4.92 (-0.34)
Hot Stock: Prana Biotechnology, Shares Gain 5.7% (PRAN)
Comtex SmarTrend(R) - Mon May 18, 10:43AM CDT
Prana Biotechnology (NASDAQ RAN) is one of today's best performing low-priced stocks, up 5.7% to $1.30 on 2.6x average daily volume. Thus far today, Prana Biotechnology has traded 888,000 shares, vs. average volume of 337,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
PRAN: 4.92 (-0.34)
Huntington's Disease Therapeutics - Global Strategic Business Report 2015: Competition in the Global HD Therapeutics Market is Non-existent
M2 - Fri May 01, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l6pzp/huntingtons) has announced the addition of the "Huntington's Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Alnylam Pharmaceuticals, Inc. - Auspex Pharmaceuticals, Inc. - Intellect Neurosciences Incorporation - Lundbeck A/S - Prana Biotechnology Limited Key Topics Covered: 1. INDUSTRY OVERVIEW 2. HD THERAPEUTICS MARKET TRENDS 3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS 4. RESEARCH BREAKTHROUGHS IN HD ARENA 5. AN OVERVIEW OF HUNTINGTON'S DISEASE 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 - The United States (13) - Canada (1) - Europe (
- - France (1) - - Germany (1) - - The United Kingdom (2) - - Italy (1) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/4l...untingtons
ASPX: 100.96 (unch), PRAN: 4.92 (-0.34)
Hot Stock: Prana Biotechnology, Shares Gain 10.1% (PRAN)
Comtex SmarTrend(R) - Tue Apr 28, 10:15AM CDT
Prana Biotechnology (NASDAQ RAN) is one of today's best performing low-priced stocks, up 10.1% to $1.26 on 5.5x average daily volume. Thus far today, Prana Biotechnology has traded 2.1 million shares, vs. average volume of 381,000 shares per day. The stock has outperformed the Dow (10.1% to the Dow's 0.1%) and outperformed the S&P 500 (10.1% to the S&P's 0.0%) during today's trading.
PRAN: 4.92 (-0.34)
PBT2 Recommended for Orphan Designation in Europe
BusinessWire - Mon Apr 27, 10:22PM CDT
Prana Biotechnology (ASX BT) (NASDAQ RAN) is pleased to announce the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).
PBT: 6.73 (-0.17), PRAN: 4.92 (-0.34)
Investors look to Lighten Up on Shares of Prana Biotechnology, Shares Down 6.5% (PRAN)
Comtex SmarTrend(R) - Fri Mar 20, 11:46AM CDT
Prana Biotechnology (NASDAQ RAN) is one of today's worst performing low-priced stocks, down 6.5% to $1.15 on 1.0x average daily volume. Prana Biotechnology has traded 713,000 shares thus far today, vs. average volume of 694,000 shares per day. The stock has underperformed the Dow (-6.5% to the Dow's 1.0%) and underperformed the S&P 500 (-6.5% to the S&P's 0.9%) during today's trading.
PRAN: 4.92 (-0.34)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.68 (-0.12), LLY: 77.23 (-0.52), ABBV: 64.03 (-0.07), PRAN: 4.92 (-0.34), PTIE: 2.32 (-0.07), CUR: 0.27 (-0.01)
The Lancet Neurology Publishes Prana's Huntington Disease Trial
BusinessWire - Wed Nov 19, 10:00AM CST
Prana Biotechnology (ASX BT)(NASDAQ RAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet Neurology.
PBT: 6.73 (-0.17), PRAN: 4.92 (-0.34)
Prana Alzheimer's disease data features at world leading conference
BusinessWire - Wed Jul 27, 11:22AM CDT
Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana's lead candidate for Huntington and Alzheimer's diseases, at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada on July 26, 2016.
PRAN: 4.92 (-0.34)
Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnology, and Sucampo Pharma
PR Newswire - Fri Jul 24, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ: PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free research report on Synergy Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SYGP On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SGYP: 4.76 (+0.03), OREX: 3.92 (-0.01), SCMP: 11.10 (+0.14), TEVA: 50.90 (+0.51), PRAN: 4.92 (-0.34)
Progressive Supranuclear Palsy Pipeline Review, H1 2015 - 6 Companies & 10 Drug Profiles
M2 - Thu Jun 25, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3grv7/progressive) has announced the addition of the "Progressive Supranuclear Palsy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlzProtect SAS - Bristol-Myers Squibb Company - Prana Biotechnology Limited - ProteoTech, Inc. - Sellas Inc. - TauRx Therapeutics Ltd. Drug Profiles - AZP-2006 - BMS-986168 - DC-TAB - DP-C016 - PBT-434 - PTI-51CH3 - PTI-51CH3 Backup - TPI-287 - TRx-0237 - zolpidem tartrate For more information visit http://www.researchandmarkets.com/research/d3...rogressive
BMY: 56.76 (-0.63), PRAN: 4.92 (-0.34)
Stock to Watch: Prana Biotechnology Up 7.4% (PRAN)
Comtex SmarTrend(R) - Mon Jun 01, 10:19AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 7.4% to $1.47 on 1.3x average daily volume. Prana Biotechnology has traded 1.0 million shares thus far today, vs. average volume of 789,000 shares per day. The stock has outperformed the Dow (7.4% to the Dow's 0.2%) and outperformed the S&P 500 (7.4% to the S&P's 0.1%) during today's trading. PRAN: 4.92 (-0.34)
European Commission Approves PBT2 Orphan Designation for Huntington's Disease
BusinessWire - Mon Jun 01, 8:00AM CDT
Prana Biotechnology Limited (ASX
BT/NASDAQ RAN) has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington's disease. PRAN: 4.92 (-0.34)
Hot Stock: Prana Biotechnology, Shares Gain 5.7% (PRAN)
Comtex SmarTrend(R) - Mon May 18, 10:43AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 5.7% to $1.30 on 2.6x average daily volume. Thus far today, Prana Biotechnology has traded 888,000 shares, vs. average volume of 337,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading. PRAN: 4.92 (-0.34)
Huntington's Disease Therapeutics - Global Strategic Business Report 2015: Competition in the Global HD Therapeutics Market is Non-existent
M2 - Fri May 01, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l6pzp/huntingtons) has announced the addition of the "Huntington's Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Alnylam Pharmaceuticals, Inc. - Auspex Pharmaceuticals, Inc. - Intellect Neurosciences Incorporation - Lundbeck A/S - Prana Biotechnology Limited Key Topics Covered: 1. INDUSTRY OVERVIEW 2. HD THERAPEUTICS MARKET TRENDS 3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS 4. RESEARCH BREAKTHROUGHS IN HD ARENA 5. AN OVERVIEW OF HUNTINGTON'S DISEASE 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 - The United States (13) - Canada (1) - Europe (
- - France (1) - - Germany (1) - - The United Kingdom (2) - - Italy (1) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/4l...untingtons ASPX: 100.96 (unch), PRAN: 4.92 (-0.34)
Hot Stock: Prana Biotechnology, Shares Gain 10.1% (PRAN)
Comtex SmarTrend(R) - Tue Apr 28, 10:15AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 10.1% to $1.26 on 5.5x average daily volume. Thus far today, Prana Biotechnology has traded 2.1 million shares, vs. average volume of 381,000 shares per day. The stock has outperformed the Dow (10.1% to the Dow's 0.1%) and outperformed the S&P 500 (10.1% to the S&P's 0.0%) during today's trading. PRAN: 4.92 (-0.34)
PBT2 Recommended for Orphan Designation in Europe
BusinessWire - Mon Apr 27, 10:22PM CDT
Prana Biotechnology (ASX
BT) (NASDAQ RAN) is pleased to announce the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC). PBT: 6.73 (-0.17), PRAN: 4.92 (-0.34)
Investors look to Lighten Up on Shares of Prana Biotechnology, Shares Down 6.5% (PRAN)
Comtex SmarTrend(R) - Fri Mar 20, 11:46AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's worst performing low-priced stocks, down 6.5% to $1.15 on 1.0x average daily volume. Prana Biotechnology has traded 713,000 shares thus far today, vs. average volume of 694,000 shares per day. The stock has underperformed the Dow (-6.5% to the Dow's 1.0%) and underperformed the S&P 500 (-6.5% to the S&P's 0.9%) during today's trading. PRAN: 4.92 (-0.34)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.68 (-0.12), LLY: 77.23 (-0.52), ABBV: 64.03 (-0.07), PRAN: 4.92 (-0.34), PTIE: 2.32 (-0.07), CUR: 0.27 (-0.01)
The Lancet Neurology Publishes Prana's Huntington Disease Trial
BusinessWire - Wed Nov 19, 10:00AM CST
Prana Biotechnology (ASX
BT)(NASDAQ RAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet Neurology. PBT: 6.73 (-0.17), PRAN: 4.92 (-0.34)
